DaVita Inc. stock gains support from higher earnings and steady guidance

Published on 09/04/2026 at 12:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita Inc. stock is trading near recent highs as investors weigh stronger mid-2026 earnings, a raised full-year EPS guidance range and a neutral analyst consensus in the Medical outpatient and home healthcare segment.

Isometrische 3D-Darstellung von Dialyseklinik, Labor, Heimversorgung und integrierter Patientenpflege — Isometrische 3D-Illustration der vollständigen Wertschöpfungskette in der Nierenversorgung von DaVita Inc. US23918K1088, Illustration mit AI erstellt.

DaVita Inc. stock (ISIN US23918K1088) has attracted renewed investor attention in early September 2026, with the shares supported by stronger mid-2026 earnings and a clear full-year earnings guidance range in the Medical outpatient and home healthcare segment. As of the last completed trading session on September 2, 2026, DaVita Inc. closed at 179.39 US dollars on the New York Stock Exchange, representing a gain of 1.85% compared with the previous close of 176.14 US dollars, according to market data compiled by Ad Hoc News based on Yahoo Finance figures. The share price level near 179 dollars stands against a backdrop of robust revenue and profit growth reported for the second quarter of 2026.

Mid-2026 earnings and guidance underpin DaVita Inc. stock

For investors, the key earnings story is that DaVita Inc. delivered a notable increase in profitability in the latest reported quarter, while also setting a clear earnings guidance corridor for the full fiscal year 2026. According to financial data for DaVita Inc. presented by The Wall Street Journal market overview for DVA, DaVita generated sales or revenue of approximately 3.55 billion US dollars in the quarter ended June 2026, marking a solid base for its dialysis and kidney care operations. In the same reporting period, net income growth reached 72.12%, highlighting that profit expanded far more quickly than revenue and signaling improved efficiency and margin control in mid-2026.

This profitability is also visible at the operating level. The same Wall Street Journal data set lists an EBITDA figure of about 738.63 million US dollars for DaVita Inc. in the quarter ended June 2026, indicating a substantial cash-earning power relative to the 3.55 billion US dollars in quarterly revenue. Taken together, the combination of 3.55 billion US dollars in sales and 738.63 million US dollars in EBITDA in June 2026 underscores a business model that is capable of converting a significant share of revenue into operating earnings, an aspect that many healthcare investors monitor closely when comparing dialysis providers.

The earnings trajectory is further framed by a clear full-year outlook. A same-day analyst coverage summary compiled by MarketBeat for DaVita Inc. states that DaVita has set its fiscal year 2026 earnings per share guidance in a range between 14.10 and 15.20 US dollars. Within that corridor, equity research analysts on average expect DaVita Inc. to post an EPS of 14.57 US dollars for the current year, placing the consensus slightly above the mid-point of the guidance range and suggesting that the market is discounting a performance closer to the upper half of management’s target band.

Analyst consensus and upcoming earnings add another layer

Beyond the current guidance range, the analyst and options landscape offers additional context for DaVita Inc. stock. In a recent commentary on derivatives activity around the shares, Zacks Investment Research describes DaVita as carrying a Zacks Rank 3, which corresponds to a Hold rating within the Medical outpatient and home healthcare industry group. This classification places DaVita in an industry subset that Zacks currently ranks within the top 20 percent of its broader industry ranking system, indicating that the segment as a whole is relatively attractive from a fundamental standpoint, even if DaVita is not singled out as a strong buy in that framework.

The timing of future earnings releases also matters for investors who track catalysts. According to the earnings estimates section of the Wall Street Journal’s DVA overview, DaVita Inc. is expected to report its third-quarter 2026 results on October 23, 2026. For that Q3 2026 reporting period, the current consensus earnings per share estimate stands at approximately 3.68 US dollars, down from 3.92 US dollars one month ago and 3.91 US dollars three months ago, as shown by the WSJ data. This downward drift in the Q3 EPS estimate suggests that some analysts have modestly recalibrated their short-term expectations, even while the full-year EPS guidance range of 14.10 to 15.20 US dollars remains intact in the MarketBeat overview.

Looking ahead to the fourth quarter of 2026, the same Wall Street Journal estimates page lists a current EPS consensus of about 4.32 US dollars, which, when combined with the mid-year performance and the 3.68 US dollars expected for the third quarter, would keep DaVita broadly in line with its full-year guidance corridor. For investors, the quantified comparison between the 14.57 US dollars full-year EPS consensus and the guidance range of 14.10 to 15.20 US dollars signals that the market expects DaVita to deliver results slightly above the mid-point of management’s target, but not necessarily at the very top of the band.

Go deeper

Further information on DaVita Inc. stock

Investors who wish to follow DaVita Inc. stock more closely can find additional regulatory filings, corporate news and intraday price updates via the dedicated topic page for the ISIN US23918K1088 and through the company's investor relations resources.

DaVita Inc. stock on ad-hoc-news.de Investor Relations

Dialysis services remain DaVita’s core business engine

The numbers in mid-2026 cannot be separated from DaVita Inc.’s position as one of the largest providers of dialysis services in the United States. A profile summary presented by CoinDesk's stock information page for DVA describes DaVita as holding a market share of around 35% in the US dialysis services market. This large share means that revenue and EBITDA figures such as the 3.55 billion US dollars in quarterly sales and the 738.63 million US dollars in EBITDA for June 2026 stem primarily from a broad base of chronic kidney disease patients receiving dialysis treatment at DaVita centers.

In practical terms, the company’s dialysis-focused business model implies that reimbursement trends from US public programs and private insurers have a direct impact on margins. The strong net income growth of 72.12% reported for the June 2026 quarter suggests that, at least during that period, DaVita succeeded in balancing reimbursement conditions, cost control and operational utilization of its treatment centers. For long-term shareholders, a key point is that the same infrastructure and market share that drove historical revenue growth can continue to support earnings as long as DaVita maintains adequate capacity utilization and navigates regulatory requirements in the kidney care field.

DaVita Inc. stock price level and investor perspective

From a pure market perspective, DaVita Inc. stock continues to trade on the New York Stock Exchange under the ticker symbol DVA, with the most recently reported closing price of 179.39 US dollars as of September 2, 2026, based on the Ad Hoc News summary of Yahoo Finance data. That closing level marked a 3.25 US dollar gain, or 1.85 percent, versus the prior closing price of 176.14 US dollars, showing that the shares responded to the context of stronger mid-2026 earnings and a clearly quantified full-year guidance range.